We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Daniel Jenkin

Daniel Jenkin

Contact information

Email
daniel.jenkin@ndm.ox.ac.uk

Website
https://www.researchgate.net/profile/Daniel-Jenkin-2

ORCID
https://orcid.org/0000-0003-3088-310X

Daniel Jenkin

MBChB, MSc, DTM&H, MRCP

CLINICAL RESEARCH FELLOW

Recent publications

Lassa fever countermeasures gather pace

Jenkin D., (2026), Nature Medicine

Safety and immunogenicity of the ChAdOx1–MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK

Borthwick N. et al, (2025), The Lancet Microbe, 6

Predictors of severity of SARS-CoV-2 infections in Brazil: Post hoc analyses of a randomised controlled trial

Conlin K. et al, (2025), Vaccine, 45

Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial

Anywaine Z. et al, (2025), Lancet Infectious Diseases

Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial

Jenkin D. et al, (2025), The Lancet Microbe